Roivant falls as lung disease drug fails in mid-stage study

Roivant Sciences

03/12/2024 12:28

** Shares of Roivant Sciences  ROIV.O  fall 2.2% to $12.20
before the bell
    ** Co says its experimental lung disease drug, namilumab,
did not meet the main and secondary goals in a mid-stage study
    ** Co was testing namilumab in patients with chronic active
pulmonary sarcoidosis, a condition in which lumps of
inflammatory cells form in the lungs
    ** Adds that it will stop further development of the drug to
treat sarcoidosis
    ** As of last close, ROIV up 11% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))